Risk Factors for Anthracycline-Induced Cardiotoxicity in Breast Cancer Treatment: A Meta-Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Jul 5

PMID 35785172

Authors

Meilin Zhang

Hongguang Yang

Changcun Xu

Feng Jin

Ang Zheng

Affiliations

Soon will be listed here.

Abstract

Background: Anthracyclines play an important role in the treatment of breast cancer (BC) and other malignant tumors. However, accompanied side-effects are non-ignorable. The purpose of this meta-analysis is to determine the risk factors for anthracycline-induced cardiotoxicity (ACT), so as to identify high-risk patients.

Methods: The search for literature was conducted in PubMed, The Cochrane Library, Embase and Web of science. Records were selected with inclusion criteria and exclusion criteria. The newcastle-ottawa scale (NOS) was used to assess the quality of literature, and Review Manager 5.3 software was used for meta-analysis.

Results: Thirteen studies met the inclusion criteria. Meta-analysis indicated that risk factors for ACT were use of trastuzumab (odds ratio [OR]: 2.84, 95% confidence interval [CI]: 2.49-3.22, 0.00001), cumulative dose of anthracyclines (OR: 1.45, 95%CI: 1.28-1.65, 0.00001), hypertension (OR: 2.95, 95%CI: 1.75-4.97, 0.0001), diabetes mellitus (DM) (OR: 1.39, 95%CI: 1.20-1.61, 0.0001), tumor metastasis (OR: 1.91, 95%CI: 1.17-3.11, 0.009) and coronary heart disease (CAD) (OR: 2.17, 95%CI: 1.50-3.15, 0.0001). In addition, our analysis revealed that body mass index (BMI) had no effect on ACT (OR: 1.18, 95%CI: 0.98-1.43, 0.08).

Conclusions: Patients with high risk for ACT can be identified by these factors. For such patients, a higher level of monitoring and protection for the cardiac function should be performed by clinicians.

Systematic Review Registration: INPLASY, identifier INPLASY202250140.

Citing Articles

Development of cancer therapy-related cardiac dysfunction in anthracycline-treated breast cancer patients: a retrospective study.

Kuroda J, Oikawa M, Tokuda E, Tachibana K, Sasaki E, Ohtake T Support Care Cancer. 2024; 33(1):8.

PMID: 39648236 PMC: 11625689. DOI: 10.1007/s00520-024-09067-0.

Anthracycline-induced hypertension in pediatric cancer survivors: unveiling the long-term cardiovascular risks.

Taghdiri A Egypt Heart J. 2024; 76(1):71.

PMID: 38849680 PMC: 11161443. DOI: 10.1186/s43044-024-00506-1.

Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management.

Askarinejad A, Alizadehasl A, Ghaffari Jolfayi A, Adimi S Cardiooncology. 2023; 9(1):46.

PMID: 38087384 PMC: 10714546. DOI: 10.1186/s40959-023-00197-8.

Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea.

Hwang H, Kim M, Jun J, Yon D Sci Rep. 2023; 13(1):21756.

PMID: 38066029 PMC: 10709414. DOI: 10.1038/s41598-023-48678-1.

Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II-III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy.

Toma R, Anca Z, Trifanescu O, Gales L, Folea A, Stanca L Med Sci Monit. 2023; 29:e941754.

PMID: 37772333 PMC: 10521333. DOI: 10.12659/MSM.941754.

References

Cappetta D, Rossi F, Piegari E, Quaini F, Berrino L, Urbanek K . Doxorubicin targets multiple players: A new view of an old problem. Pharmacol Res. 2017; 127:4-14. DOI: 10.1016/j.phrs.2017.03.016. View

Yoodee J, Sookprasert A, Sanguanboonyaphong P, Chanthawong S, Seateaw M, Subongkot S . An Exploration of Heart Failure Risk in Breast Cancer Patients Receiving Anthracyclines with or without Trastuzumab in Thailand: A Retrospective Study. Clin Pract. 2021; 11(3):484-493. PMC: 8395478. DOI: 10.3390/clinpract11030064. View

Lorusso D, Sabatucci I, Maltese G, Lepori S, Tripodi E, Bogani G . Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis. Tumori. 2019; 105(4):282-287. DOI: 10.1177/0300891619839308. View

Baron F, Efficace F, Cannella L, Muus P, Trisolini S, Halkes C . Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study. Am J Hematol. 2020; 95(7):749-758. DOI: 10.1002/ajh.25795. View

Wang B, Yu Y, Zhang Y, Hao X, Yang S, Zhao H . Right ventricular dysfunction in patients with diffuse large B-cell lymphoma undergoing anthracycline-based chemotherapy: a 2D strain and 3D echocardiography study. Int J Cardiovasc Imaging. 2021; 37(4):1311-1319. DOI: 10.1007/s10554-020-02120-z. View

Upshaw J, Ruthazer R, Miller K, Parsons S, Erban J, ONeill A . Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off. Clin Breast Cancer. 2019; 19(4):259-267.e1. PMC: 6667295. DOI: 10.1016/j.clbc.2019.04.012. View

Fogarassy G, Vathy-Fogarassy A, Kenessey I, Kasler M, Forster T . Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer - A real-world data-based, nationwide classification analysis. Int J Cardiol. 2019; 285:47-52. DOI: 10.1016/j.ijcard.2019.03.013. View

van Dalen E, Caron H, Dickinson H, Kremer L . Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011; (6):CD003917. PMC: 6457676. DOI: 10.1002/14651858.CD003917.pub4. View

Patnaik J, Byers T, DiGuiseppi C, Dabelea D, Denberg T . Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011; 13(3):R64. PMC: 3218953. DOI: 10.1186/bcr2901. View

10.

Kim Y, Cho H, Lee N, Jung S, Sim S, Park I . Doxorubicin-induced heart failure in cancer patients: A cohort study based on the Korean National Health Insurance Database. Cancer Med. 2018; 7(12):6084-6092. PMC: 6308087. DOI: 10.1002/cam4.1886. View

11.

Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W . Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol. 2019; 73(22):2859-2868. PMC: 6557296. DOI: 10.1016/j.jacc.2019.03.495. View

12.

Meessen J, Cardinale D, Ciceri F, Sandri M, Civelli M, Bottazzi B . Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial. ESC Heart Fail. 2020; 7(4):1452-1466. PMC: 7373944. DOI: 10.1002/ehf2.12695. View

13.

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni C, Veglia F . Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; 131(22):1981-8. DOI: 10.1161/CIRCULATIONAHA.114.013777. View

14.

Chavez-MacGregor M, Niu J, Zhang N, Elting L, Smith B, Banchs J . Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer. J Clin Oncol. 2015; 33(19):2176-83. PMC: 4979214. DOI: 10.1200/JCO.2014.58.9465. View

15.

Kotwinski P, Smith G, Cooper J, Sanders J, Ma L, Teis A . Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer. PLoS One. 2016; 11(12):e0165262. PMC: 5135038. DOI: 10.1371/journal.pone.0165262. View

16.

Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen P . New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst. 2008; 100(15):1058-67. DOI: 10.1093/jnci/djn206. View

17.

Baldini E, Prochilo T, Salvadori B, Bolognesi A, Aldrighetti D, Venturini M . Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety. Br J Cancer. 2004; 91(1):45-9. PMC: 2364750. DOI: 10.1038/sj.bjc.6601883. View

18.

Herrmann J . Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020; 17(8):474-502. PMC: 8782611. DOI: 10.1038/s41569-020-0348-1. View

19.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

20.

Cil T, Kaplan A, Altintas A, Akin A, Alan S, Isikdogan A . Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series. Clin Drug Investig. 2009; 29(2):131-7. DOI: 10.2165/0044011-200929020-00007. View